Leaflet RYMPHYSIA 500mg powder and solvent for solution for infusion

Product code:
W68873001
Quantity:
1
Indicated for:
alpha-1 antitrypsin deficiency
Route of administration:
infusion
Substance:
human alfa-1 proteinase inhibitor (alpha-1 proteinase inhibitor)
ATC
B02AB02 — Blood and blood forming organs | Antifibrinolytics | Proteinase inhibitors
Human alpha-1 proteinase inhibitor is used for the treatment of alpha-1 antitrypsin deficiency, a genetic condition that can lead to lung diseases such as emphysema. It works by protecting lung tissue from enzymatic degradation.

The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse reactions during the infusion.

Side effects may include headache, fever, dizziness, or injection site reactions. In rare cases, severe allergic reactions may occur.

This medication is not recommended for patients with hypersensitivity to human plasma proteins or severe IgA deficiency.

General data about RYMPHYSIA 500mg

Substance:
human alfa-1 proteinase inhibitor
Date of latest medicines list:
01-07-2022
Product code:
W68873001
Concentration:
500mg
Pharmaceutical form:
powder and solvent for solution for infusion
Quantity:
1
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
TAKEDA MANUFACTURING AUSTRIA AG - AUSTRIA
Holder:
TAKEDA MANUFACTURING AUSTRIA AG - AUSTRIA
Number:
14494/2022/01
Shelf life:
24 months-after packaging for sale;after reconstitution-it is used immediately

Concentrations available for human alfa-1 proteinase inhibitor

  • 1000mg
  • 500mg